Download PDF
Am J Perinatol 2021; 38(13): 1380-1385
DOI: 10.1055/s-0040-1712966
Original Article

Fibroblast Growth Factor 21 and Metabolic Dysfunction in Women with a Prior Glucose-Intolerant Pregnancy

Celeste Durnwald
1   Department of Obstetrics and Gynecology, University of Pennsylvania, Philadelphia, Pennsylvania
,
Lisa Mele
2   George Washington University Biostatistics Center, Washington, District of Columbia
,
Mark B. Landon
3   Department of Obstetrics and Gynecology, The Ohio State University, Columbus, Ohio
,
Michael W. Varner
4   Department of Obstetrics and Gynecology, University of Utah Health Sciences Center, Salt Lake City, Utah
,
Brian M. Casey
5   Department of Obstetrics and Gynecology, University of Texas Southwestern Medical Center, Dallas, Texas
,
Uma M. Reddy
6   Eunice Kennedy Shriver National Institute of Child Health and Human Development (U.M.R.), Bethesda, Maryland
,
Ronald J. Wapner
7   Department of Obstetrics and Gynecology, Columbia University, New York, New York
,
Dwight J. Rouse
8   Department of Obstetrics and Gynecology, Brown University, Providence, Rhode Island
,
Alan T. N. Tita
9   Department of Obstetrics and Gynecology, University of Alabama at Birmingham, Birmingham, Alabama
,
John M. Thorp Jr.
10   Department of Obstetrics and Gynecology, University of North Carolina, Chapel Hill, North Carolina
,
Edward K. Chien
11   Department of Obstetrics and Gynecology, MetroHealth Medical Center – Case Western Reserve University, Cleveland, Ohio
,
George R. Saade
12   Department of Obstetrics and Gynecology, University of Texas Medical Branch, Galveston, Texas
,
Alan M. Peaceman
13   Department of Obstetrics and Gynecology, Northwestern University, Chicago, Illinois
,
Sean C. Blackwell
14   Department of Obstetrics and Gynecology, University of Texas Health Science Center at Houston-Children's Memorial Hermann Hospital, Houston, Texas
,
for the Eunice Kennedy Shriver National Institute of Child Health Human Development (NICHD) Maternal Fetal Medicine Units (MFMU) Network › Author Affiliations Funding This study was supported by grants from the Eunice Kennedy Shriver National Institute of Child Health and Human Development (grant numbers: HD27915, HD36801, HD34208, HD34116, HD40485, HD40500, HD27869, HD40560, HD40544, HD53097, HD40512, and HD40545) and the National Institutes of Health's National Center for Advancing Translational Sciences (grant numbers: UL1TR001070 and UL1TR000439). Comments and views of the authors do not necessarily represent views of the National Institutes of Health.
› Further Information
Also available at
    Permissions and Reprints

Abstract

Objective We sought to determine if there is an association between fibroblast growth factor 21 (FGF21) levels and a history of gestational diabetes mellitus (GDM) in women with and without metabolic dysfunction, defined as a diagnosis of metabolic syndrome or type 2 diabetes (T2DM), 5 to 10 years following participation in a multiple cohort GDM study.

Study Design At 5 to 10 years after index pregnancy, women underwent a follow-up visit and were categorized as having no metabolic syndrome, metabolic syndrome, or T2DM. FGF21 levels were compared between women who did and did not have a history of GDM using multivariable linear regression.

Results Among 1,889 women, 950 underwent follow-up and 796 had plasma samples analyzed (413 GDM and 383 non-GDM). Total 30.7% of women had been diagnosed with T2DM or metabolic syndrome. Overall, there was no difference in median FGF21 levels in pg/mL between the prior GDM and non-GDM groups (p = 0.12), and the lack of association was observed across all three metabolic categories at follow-up (p for interaction = 0.70).

Conclusion There was no association between FGF21 levels and prior history of mild GDM in women with and without metabolic dysfunction 5 to 10 years after the index pregnancy (ClinicalTrials.gov number, NCT00069576, original trial).

Keywords

fibroblast growth factor - gestational diabetes - glucose intolerance - metabolic syndrome

Note

This study was presented in part at the 2018 Annual Scientific Meeting of the Society for Maternal–Fetal Medicine (January 29 to February 3, 2017), Dallas, TX.


* See [Supplementary Material] (available in the online version) for list of other members of the NICHD MFMU Network, Bethesda, MD.


Supplementary Material



Publication History

Received: 20 May 2019

Accepted: 28 April 2020

Article published online:
23 June 2020

© 2020. Thieme. All rights reserved.

Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA

 

  • References

  • 1 Bellamy L, Casas JP, Hingorani AD, Williams D. Type 2 diabetes mellitus after gestational diabetes: a systematic review and meta-analysis. Lancet 2009; 373 (9677): 1773-1779
    CrossrefPubMedGoogle Scholar
  • 2 Kim C, Newton KM, Knopp RH. Gestational diabetes and the incidence of type 2 diabetes: a systematic review. Diabetes Care 2002; 25 (10) 1862-1868
    CrossrefPubMedGoogle Scholar
  • 3 Heitritter SM, Solomon CG, Mitchell GF, Skali-Ounis N, Seely EW. Subclinical inflammation and vascular dysfunction in women with previous gestational diabetes mellitus. J Clin Endocrinol Metab 2005; 90 (07) 3983-3988
    CrossrefPubMedGoogle Scholar
  • 4 Li JW, He SY, Liu P, Luo L, Zhao L, Xiao YB. Association of gestational diabetes mellitus (GDM) with subclinical atherosclerosis: a systemic review and meta-analysis. BMC Cardiovasc Disord 2014; 14: 132
    CrossrefPubMedGoogle Scholar
  • 5 Ong KL, Januszewski AS, O'Connell R. et al; FIELD study investigators. Relationship of fibroblast growth factor 21 with baseline and new on-study microvascular disease in the Fenofibrate Intervention and Event Lowering in Diabetes study. Diabetologia 2015; 58 (09) 2035-2044
    CrossrefPubMedGoogle Scholar
  • 6 Yuan D, Wu BJ, Henry A, Rye KA, Ong KL. Role of fibroblast growth factor 21 in gestational diabetes mellitus: A mini-review. Clin Endocrinol (Oxf) 2019; 90 (01) 47-55
    CrossrefPubMedGoogle Scholar
  • 7 Wang D, Zhu W, Li J, An C, Wang Z. Serum concentrations of fibroblast growth factors 19 and 21 in women with gestational diabetes mellitus: association with insulin resistance, adiponectin, and polycystic ovary syndrome history. PLoS One 2013; 8 (11) e81190
    CrossrefPubMedGoogle Scholar
  • 8 Li SM, Wang WF, Zhou LH. et al. Fibroblast growth factor 21 expressions in white blood cells and sera of patients with gestational diabetes mellitus during gestation and postpartum. Endocrine 2015; 48 (02) 519-527
    CrossrefPubMedGoogle Scholar
  • 9 Tan BK, Sivakumar K, Bari MF, Vatish M, Randeva HS. Lower cerebrospinal fluid/plasma fibroblast growth factor 21 (FGF21) ratios and placental FGF21 production in gestational diabetes. PLoS One 2013; 8 (06) e65254
    CrossrefPubMedGoogle Scholar
  • 10 Chen C, Cheung BM, Tso AW. et al. High plasma level of fibroblast growth factor 21 is an Independent predictor of type 2 diabetes: a 5.4-year population-based prospective study in Chinese subjects. Diabetes Care 2011; 34 (09) 2113-2115
    CrossrefPubMedGoogle Scholar
  • 11 Bobbert T, Schwarz F, Fischer-Rosinsky A. et al. Fibroblast growth factor 21 predicts the metabolic syndrome and type 2 diabetes in Caucasians. Diabetes Care 2013; 36 (01) 145-149
    CrossrefPubMedGoogle Scholar
  • 12 Landon MB, Spong CY, Thom E. et al; Eunice Kennedy Shriver National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network. A multicenter, randomized trial of treatment for mild gestational diabetes. N Engl J Med 2009; 361 (14) 1339-1348
    CrossrefPubMedGoogle Scholar
  • 13 Landon MB, Rice MM, Varner MW. et al; Eunice Kennedy Shriver National Institute of Child Health and Human Development Maternal-Fetal Medicine Units (MFMU) Network. Mild gestational diabetes mellitus and long-term child health. Diabetes Care 2015; 38 (03) 445-452
    CrossrefPubMedGoogle Scholar
  • 14 Grundy SM, Cleeman JI, Daniels SR. et al; American Heart Association; National Heart, Lung, and Blood Institute. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2005; 112 (17) 2735-2752
    CrossrefPubMedGoogle Scholar
  • 15 American Diabetes Association. 2. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes-2018 . Diabetes Care 2018; 41 (Suppl. 01) S13-S27
    CrossrefPubMedGoogle Scholar
  • 16 Mraz M, Bartlova M, Lacinova Z. et al. Serum concentrations and tissue expression of a novel endocrine regulator fibroblast growth factor-21 in patients with type 2 diabetes and obesity. Clin Endocrinol (Oxf) 2009; 71 (03) 369-375
    CrossrefPubMedGoogle Scholar
  • 17 Zhang F, Yu L, Lin X. et al. Minireview: roles of fibroblast growth factors 19 and 21 in metabolic regulation and chronic diseases. Mol Endocrinol 2015; 29 (10) 1400-1413
    CrossrefPubMedGoogle Scholar
  • 18 Megia A, Gil-Lluis P, Näf S. et al. Cord blood FGF21 in gestational diabetes and its relationship with postnatal growth. Acta Diabetol 2015; 52 (04) 693-700
    CrossrefPubMedGoogle Scholar
  • 19 Gabbe SG, Landon MB, Warren-Boulton E, Fradkin J. Promoting health after gestational diabetes: a National Diabetes Education Program call to action. Obstet Gynecol 2012; 119 (01) 171-176
    CrossrefPubMedGoogle Scholar
  • 20 Nielsen KK, Kapur A, Damm P, de Courten M, Bygbjerg IC. From screening to postpartum follow-up - the determinants and barriers for gestational diabetes mellitus (GDM) services, a systematic review. BMC Pregnancy Childbirth 2014; 14: 41
    CrossrefPubMedGoogle Scholar
  • 21 Ozuguz U, Isik S, Berker D. et al. Gestational diabetes and subclinical inflammation: evaluation of first year postpartum outcomes. Diabetes Res Clin Pract 2011; 94 (03) 426-433
    CrossrefPubMedGoogle Scholar
  • 22 Durnwald CP, Downes K, Leite R, Elovitz M, Parry S. Predicting persistent impaired glucose tolerance in patients with gestational diabetes: The role of high sensitivity CRP and adiponectin. Diabetes Metab Res Rev 2018; 34 (02) 34
    CrossrefPubMedGoogle Scholar
  • 23 Woo YC, Lee CH, Fong CH. et al. Serum fibroblast growth factor 21 is a superior biomarker to other adipokines in predicting incident diabetes. Clin Endocrinol (Oxf) 2017; 86 (01) 37-43
    CrossrefPubMedGoogle Scholar
  • 24 Ong KL, Januszewski AS, O'Connell R. et al. The relationship of fibroblast growth factor 21 with cardiovascular outcome events in the Fenofibrate Intervention and Event Lowering in Diabetes study. Diabetologia 2015; 58 (03) 464-473
    CrossrefPubMedGoogle Scholar
  • 25 Xu J, Stanislaus S, Chinookoswong N. et al. Acute glucose-lowering and insulin-sensitizing action of FGF21 in insulin-resistant mouse models--association with liver and adipose tissue effects. Am J Physiol Endocrinol Metab 2009; 297 (05) E1105-E1114
    CrossrefPubMedGoogle Scholar
  • 26 Xu J, Lloyd DJ, Hale C. et al. Fibroblast growth factor 21 reverses hepatic steatosis, increases energy expenditure, and improves insulin sensitivity in diet-induced obese mice. Diabetes 2009; 58 (01) 250-259
    CrossrefPubMedGoogle Scholar